6. Parkinson disease Clinical trials / Disease details
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05581823 (ClinicalTrials.gov) | October 19, 2022 | 12/10/2022 | Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants | A Phase 1, Open-label, Fixed-sequence, Crossover Trial to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Induction by Carbamazepine on the Steady-state Pharmacokinetics of Tavapadon in Healthy Adult Participants | Parkinson Disease | Drug: Tavapadon;Drug: Carbamazepine | Cerevel Therapeutics, LLC | NULL | Active, not recruiting | 18 Years | 55 Years | All | 16 | Phase 1 | United States |
| 2 | NCT05635461 (ClinicalTrials.gov) | October 9, 2022 | 7/11/2022 | Relative Bioavailability and Food Effect Study of CVN424 | A Randomized, Open-Label, Single Oral Dose, Three-Way Cross-Over Trial to Evaluate the Relative Bioavailability of CVN424 Suspension &Tablet Formulations Including an Assessment of the Effect of Food on the Tablet Formulation in Healthy Adult Volunteers | Parkinson Disease | Drug: CVN424 | Cerevance Beta, Inc. | NULL | Completed | 18 Years | 55 Years | All | 32 | Phase 1 | United States |
| 3 | NCT05523570 (ClinicalTrials.gov) | August 22, 2022 | 24/8/2022 | A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension | Phase 1, Non-randomized, Single Ascending Doses (SAD) Study Following Single Injection in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HNC364 Injectable Suspension | Parkinson's Disease | Drug: HNC364 | Guangzhou Henovcom Bioscience Co. Ltd. | NULL | Recruiting | 18 Years | 45 Years | All | 18 | Phase 1 | United States |
| 4 | NCT05670782 (ClinicalTrials.gov) | July 19, 2022 | 21/12/2022 | A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants With Parkinson's Disease | A Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KM-819 in Healthy Older Adults and Participants With Parkinson's Disease | Parkinson Disease | Drug: KM-819;Drug: Placebo | FAScinate Therapeutics Inc. | Parexel | Recruiting | 40 Years | N/A | All | 330 | Phase 2 | United States |
| 5 | NCT03903549 (ClinicalTrials.gov) | July 15, 2022 | 3/4/2019 | Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers | A Positron Emission Tomography (PET) Study to Investigate [18F]D6-FP-DTBZ ([18F]P17-059) for Potential Use as a Radioligand for Vesicular Monoamine Transporter (VMAT2) | Parkinson Disease | Drug: [18F]P17-059 | Five Eleven Pharma, Inc. | NULL | Completed | 45 Years | 90 Years | All | 4 | Phase 1 | United States |
| 6 | NCT05128175 (ClinicalTrials.gov) | October 29, 2021 | 27/10/2021 | Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions | An Open-label, Balanced, Randomized, Five-treatment, Five-period, Five-sequence, Multiple Oral Dose, Crossover Comparative Bioavailability Study of Different Strengths of Carbidopa/Levodopa Extended-release Tablets With Carbidopa and Levodopa Tablets in Normal, Healthy Adult Human Subjects Under Fasting and Fed Conditions | Parkinson Disease | Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets | Shanghai WD Pharmaceutical Co., Ltd. | NULL | Recruiting | 18 Years | 45 Years | All | 15 | Phase 1 | India |
| 7 | NCT05220072 (ClinicalTrials.gov) | August 28, 2021 | 18/11/2021 | Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156 | An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of Carbon-14 BIA 28-6156 in Healthy Male Subjects | Parkinson Disease | Drug: Carbon-14 BIA 28-6156 | Bial R&D Investments, S.A. | NULL | Completed | 30 Years | 65 Years | Male | 6 | Phase 1 | United Kingdom |
| 8 | NCT04867642 (ClinicalTrials.gov) | April 29, 2021 | 27/4/2021 | A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease | A First-In-Human, Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled, Single- and Multiple-Dose, Dose-Escalating Study Evaluating the Safety, Tolerability, and Pharmacokinetics of UCB0022 in Healthy Participants and Participants With Parkinson's Disease | Healthy Study Participants;Parkinson's Disease | Drug: UCB0022;Other: Placebo | UCB Biopharma SRL | NULL | Active, not recruiting | 18 Years | 75 Years | All | 100 | Phase 1 | United Kingdom |
| 9 | ChiCTR2100045506 | 2021-04-19 | 2021-04-18 | The immediate effects of rhythmic auditory stimulation on upper-limb movements in patients with Parkinson’s disease | The immediate effects of rhythmic auditory stimulation on upper-limb movements in patients with Parkinson’s disease | Parkinson Disease | Healthy people group:Different frequency of RAS;Parkinson's disease group:Different frequency of RAS; | Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology | NULL | Recruiting | Male | Healthy people group:36;Parkinson's disease group:36; | China | |||
| 10 | NCT04350177 (ClinicalTrials.gov) | February 16, 2021 | 26/12/2019 | A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients | A Phase I, Randomized Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Determine the Safety, Tolerability and Pharmacokinetics (PK) of IkT-148009 in Older Adult and Elderly Healthy Volunteers With Extension Into Parkinson's Patients | Healthy Elderly;Parkinson Disease | Drug: IkT-148009;Drug: Placebo | Inhibikase Therapeutics, Inc. | NULL | Completed | 55 Years | 70 Years | All | 101 | Phase 1 | United States |
| 11 | NCT04593511 (ClinicalTrials.gov) | February 2, 2021 | 21/9/2020 | to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers | An Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 After a Single Intramuscular Injection | Parkinson's Disease | Drug: LY03009 F1;Drug: LY03009 F2;Drug: LY03009 F3;Drug: LY03009 F4 | Luye Pharma Group Ltd. | NULL | Enrolling by invitation | 18 Years | 65 Years | All | 40 | Phase 1 | Australia |
| 12 | NCT04625361 (ClinicalTrials.gov) | January 20, 2021 | 9/11/2020 | Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects | A Single Center, Randomized, Double-Blind, Placebo-Controlled Study of Single/Multiple Ascending Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, and Single Center, Randomized, Double-Blind, Two Periods, Crossover, Food Effect Study of HEC122505MsOH Tablets in Healthy Chinese Subjects | Parkinson Disease | Drug: HEC122505MsOH | Sunshine Lake Pharma Co., Ltd. | NULL | Recruiting | 18 Years | 45 Years | All | 102 | Phase 1 | China |
| 13 | JPRN-jRCT2051200104 | 06/01/2021 | 24/12/2020 | A Phase 1 Study of KK6483 in Healthy Male Volunteers | A Phase 1 Study of KK6483 in Healthy Male Volunteers | Parkinson's disease | A single oral administration of the investigational product, KK6483C in combination with the existing levodopa (LD)/carbidopa (CD)/entacapone (ET) | Yagi Michio | NULL | Complete | >= 20age old | < 45age old | Male | 40 | Phase 1 | Japan |
| 14 | NCT04651153 (ClinicalTrials.gov) | December 14, 2020 | 25/11/2020 | A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD) | A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Healthy Male Study Participants and Multiple Ascending Doses in Patients With Parkinson's Disease | Parkinson's Disease | Drug: UCB7853;Other: Placebo | UCB Biopharma SRL | NULL | Active, not recruiting | 18 Years | 80 Years | All | 57 | Phase 1 | Netherlands;United Kingdom |
| 15 | NCT03665493 (ClinicalTrials.gov) | September 30, 2020 | 4/9/2018 | Dopamine Effect on Inhibitory Control | Dopamine Effect on Inhibitory Control | Idiopathic Parkinson's Disease | Drug: PD patients H&Y=1.5-2 Medications ON;Drug: PD patients H&Y=1.5-2 Medications OFF;Behavioral: Healthy age-matched controls;Drug: PD patients H&Y=3 Medications OFF;Drug: PD patients H&Y=3 Medications ON | Giovanni Mirabella | NULL | Recruiting | 40 Years | 70 Years | All | 102 | N/A | Italy |
| 16 | NCT04591535 (ClinicalTrials.gov) | September 28, 2020 | 11/9/2020 | PK Study of WD-1603 in Healthy Subjects | An Open Label, Balanced, Randomised, Four-treatment, Four-period, Four-sequence, Single Oral Dose, Crossover PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fed Conditions | Parkinson Disease | Drug: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS | Hong Kong WD Pharmaceutical Co., Limited | NULL | Recruiting | 18 Years | 45 Years | All | 8 | Phase 1 | India |
| 17 | NCT04553978 (ClinicalTrials.gov) | September 18, 2020 | 13/9/2020 | A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions | An Open Label, Balanced, Randomised, 2-treatment, 2-period, 2-sequence, Single Oral Dose, Corssover Comparative PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fasting Conditions | Parkinson Disease | Drug: WD-1603 | Hong Kong WD Pharmaceutical Co., Limited | NULL | Not yet recruiting | 18 Years | 45 Years | All | 8 | Phase 1 | NULL |
| 18 | ChiCTR2000035564 | 2020-08-17 | 2020-08-13 | Pharmacokinetics and Bioequivalence study of Pramipexole Extended-Release Tablets in Healthy Chinese Volunteers | Pharmacokinetics and Bioequivalence study of Pramipexole Extended-Release Tablets in Healthy Chinese Volunteers | Parkinson’s disease | fasting administration group-TR:phase I: Pramipexole Extended-Release Tablets; phase II: Reference preparation;fasting administration group-RT:phase I: Reference preparation: pahse II: Test preparation;high-fat postprandial administration group-TR:phase I: Pramipexole Extended-Release Tablets; phase II: Reference preparation;high-fat postprandial administration group-RT:phase I: Pramipexole Extended-Release Tablets; phase II: Reference preparation; | West China Hospital of Sichuan University | NULL | Recruiting | 18 | 65 | Both | fasting administration group-TR:28;fasting administration group-RT:28;high-fat postprandial administration group-TR:28;high-fat postprandial administration group-RT:28; | Phase 1 | China |
| 19 | NCT04513340 (ClinicalTrials.gov) | August 13, 2020 | 12/8/2020 | WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects | AN OPEN LABEL, BALANCED, RANDOMISED, FOUR-TREATMENT, FOUR-PERIOD, FOUR-SEQUENCE, SINGLE INTRA-ORAL AND ORAL DOSE, CROSSOVER PHARMACOKINETICS STUDY OF WD-1603 EXTENDED-RELEASE CARBIDOPA/LEVODOPA TABLETS 25/100MG IN NORMAL, HEALTHY, ADULT HUMAN SUBJECTS UNDER FASTING AND FED CONDITIONS | Parkinson Disease | Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS | Hong Kong WD Pharmaceutical Co., Limited | NULL | Recruiting | 18 Years | 45 Years | All | 8 | Phase 1 | India |
| 20 | NCT04384666 (ClinicalTrials.gov) | June 2, 2020 | 8/5/2020 | A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers | A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers | Parkinson Disease | Drug: LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection);Other: Neupro 4 mg / 24 Hr. Transdermal Patch | Luye Pharma Group Ltd. | NULL | Completed | 18 Years | 45 Years | All | 56 | Phase 1 | United States |
| 21 | NCT04342273 (ClinicalTrials.gov) | March 31, 2020 | 8/4/2020 | A Through QT/QTc Study of KW-6356 | A Through QT/QTc Study of KW-6356 in Japanese Healthy Adults | Parkinson's Disease | Drug: KW-6356;Drug: Placebo;Drug: Moxifloxacin | Kyowa Kirin Co., Ltd. | NULL | Completed | 20 Years | 54 Years | All | 128 | Phase 1 | Japan |
| 22 | NCT04322227 (ClinicalTrials.gov) | January 23, 2020 | 29/1/2020 | Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects | Interventional, Randomized, Double-blind, Placebo-controlled Three-way Crossover Study Investigating the Pharmacodynamic Effects of Two Doses of Foliglurax Using Electroencephalography in Patients With Parkinson's Disease and in Healthy Subjects | Parkinson Disease;Healthy | Drug: Foliglurax 10 mg (treatment A);Drug: Foliglurax 30 mg (treatment B);Drug: Placebo (treatment C) | H. Lundbeck A/S | NULL | Terminated | 50 Years | 70 Years | All | 6 | Phase 1 | France |
| 23 | NCT04164121 (ClinicalTrials.gov) | December 17, 2019 | 12/11/2019 | A Randomized, Double-blind, Placebo-controlled, Single-dose, Multiple-dose, Incremental Tolerance and Pharmacokinetics Study of Phenlarmide Tablets in Chinese Healthy Adult Volunteers | A Randomized, Double-blind, Placebo-controlled, Single-dose, Multiple-dose, Incremental Tolerance and Pharmacokinetics Study of Phenlarmide Tablets in Chinese Healthy Adult Volunteers | Parkinson Disease | Drug: Phenlarmide Tablets;Drug: Placebos | Yiling Pharmaceutical Inc. | NULL | Completed | 18 Years | 65 Years | All | 36 | Phase 1 | China |
| 24 | NCT04175132 (ClinicalTrials.gov) | November 12, 2019 | 12/11/2019 | Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD) | Interventional, Open-label, Positron Emission Tomography (PET) Study With [11C]-PXT012253 Investigating the Brain mGlu4 Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of Foliglurax in Healthy Subjects and Patients With Parkinson's Disease | Healthy;Parkinson Disease | Drug: foliglurax | H. Lundbeck A/S | NULL | Terminated | 50 Years | 70 Years | All | 6 | Phase 1 | Sweden |
| 25 | NCT04165837 (ClinicalTrials.gov) | October 14, 2019 | 13/11/2019 | Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects | Parkinson's Disease | Drug: FB-101;Drug: Placebo | 1ST Biotherapeutics, Inc. | NULL | Completed | 19 Years | 55 Years | All | 24 | Phase 1 | United States |
| 26 | NCT04075318 (ClinicalTrials.gov) | August 29, 2019 | 5/8/2019 | Study of UB-312 in Healthy Participants and Parkinson's Disease Patients | A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease | Parkinson's Disease;Parkinsonism | Biological: UB-312;Biological: Placebo | United Neuroscience Ltd. | Centre for Human Drug Research, Netherlands;Worldwide Clinical Trials;Vaxxinity, Inc. | Active, not recruiting | 40 Years | 85 Years | All | 70 | Phase 1 | Netherlands |
| 27 | NCT04043338 (ClinicalTrials.gov) | August 11, 2019 | 24/7/2019 | Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study Investigating the Safety, Tolerability, and Pharmacokinetics of XC130-A10H in Healthy Adult Subjects | Parkinson's Disease | Drug: XC130-A10H;Drug: Placebo | Xoc Pharmaceuticals | Celerion | Active, not recruiting | 18 Years | 75 Years | All | 56 | Phase 1 | United States |
| 28 | ChiCTR1900021708 | 2019-07-01 | 2019-03-05 | Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphi | Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphism | Parkinson's Disease | Healthy control group:No;tremor-dominant phenotype PD patients group:pramipexole; | Department of Neurology, Brain Hospital Affiliated to Nanjing Medical University | NULL | Pending | 50 | 70 | Both | Healthy control group:80;tremor-dominant phenotype PD patients group:80; | China | |
| 29 | NCT04875962 (ClinicalTrials.gov) | May 6, 2019 | 3/5/2021 | A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD) | A Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD) | Parkinson's Disease | Drug: UCB0599;Drug: Placebo | UCB Biopharma S.P.R.L. | NULL | Completed | 40 Years | 80 Years | All | 31 | Phase 1 | United States |
| 30 | NCT03820037 (ClinicalTrials.gov) | March 2019 | 25/1/2019 | Relative Bioavailability and Bioequivalence of Opicapone | A Phase I, Open-Label, Randomised, Three-Period, Three-Sequence, Partial Replicate Crossover Study to Investigate the Relative Bioavailability and Bioequivalence of Opicapone Obtained From Two Different Sources, Under Fasting Conditions After Single-dose Administration in Healthy Subjects | Parkinson Disease | Drug: Ongentys;Drug: BIA 9-1067 (test) | Bial - Portela C S.A. | NULL | Not yet recruiting | 18 Years | 55 Years | All | 45 | Phase 1 | United Kingdom |
| 31 | NCT03830528 (ClinicalTrials.gov) | February 26, 2019 | 3/2/2019 | A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects | A Phase I Study of KW-6356 in Japanese and Caucasian Healthy Adults | Parkinson's Disease | Drug: KW-6356 Low Dose;Drug: KW-6356 Middle Dose;Drug: KW-6356 High Dose;Drug: KW-6356 X Dose;Drug: KW-6356 Y Dose;Drug: Placebo | Kyowa Kirin Co., Ltd. | NULL | Completed | 20 Years | 44 Years | Male | 48 | Phase 1 | Japan |
| 32 | EUCTR2018-002877-23-AT (EUCTR) | 21/01/2019 | 07/12/2018 | Oxytocin and social attention in healthy controls and patients with Parkinson's disease. A randomised, double-blind, placebo-controlled, crossover eye tracking study. - Oxytocin in healthy controls and PD | Oxytocin and social attention in healthy controls and patients with Parkinson's disease. A randomised, double-blind, placebo-controlled, crossover eye tracking study. - Oxytocin in healthy controls and PD | Social functioning in Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Syntocinon 40 IU/ml nasal spray INN or Proposed INN: Synthetic Oxytocin Other descriptive name: OXYTOCIN SYNTHETIC | Abteilung für Neurologie der Medizinischen Universität Innsbruck | NULL | Not Recruiting | Female: no Male: yes | 76 | Phase 2 | Austria | ||
| 33 | NCT03826134 (ClinicalTrials.gov) | January 17, 2019 | 30/1/2019 | A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects | Interventional, Phase I, Open-label, First in Human, Single-center Positron Emission Tomography (PET) Study Investigating Test-retest Properties of [11C]-PXT012253 as a Radiotracer in Healthy Subjects | Parkinson Disease | Drug: [11C]PXT012253 | H. Lundbeck A/S | NULL | Completed | 20 Years | 50 Years | All | 7 | Early Phase 1 | Sweden |
| 34 | NCT03822364 (ClinicalTrials.gov) | November 26, 2018 | 18/12/2018 | Staccato Apomorphine Single and Multi Dose PK | A Randomized Study of the Safety, Tolerability, and Pharmacokinetics of AZ-009 (Staccato Apomorphine) in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZ-009 in Subjects With Parkinson's Disease | Parkinson Disease | Drug: 009-1;Drug: active comparator;Drug: 009-0;Drug: 009-2;Drug: 009-3;Drug: 009-4;Drug: 009-5 | Alexza Pharmaceuticals, Inc. | NULL | Completed | 18 Years | 60 Years | All | 56 | Phase 1 | Netherlands |
| 35 | NCT03733561 (ClinicalTrials.gov) | November 9, 2018 | 6/11/2018 | A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro | A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers | Parkinson Disease | Drug: LY03003;Drug: Neupro 4Mg/24Hr Transdermal Patch | Luye Pharma Group Ltd. | NULL | Completed | 18 Years | 45 Years | All | 40 | Phase 1 | United States |
| 36 | NCT03611569 (ClinicalTrials.gov) | July 25, 2018 | 26/7/2018 | Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease | Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease | Healthy;Parkinson Disease | Drug: Lu AF82422;Drug: Placebo | H. Lundbeck A/S | NULL | Completed | 18 Years | 80 Years | All | 74 | Phase 1 | United States |
| 37 | NCT03510572 (ClinicalTrials.gov) | June 4, 2018 | 17/4/2018 | Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain | Clinical Evaluation of [18F]PI-2620 Positron Emission Computed Tomography for Imaging Tau Protein in Patients With Tauopathies and Healthy Volunteers: Phase 0 Study | Healthy Volunteer;Alzheimer Disease;Frontotemporal Dementia;Parkinson Disease | Drug: [18F]PI-2620 | Asan Medical Center | Korea Health Industry Development Institute | Completed | 40 Years | 80 Years | All | 20 | Early Phase 1 | Korea, Republic of |
| 38 | NCT03587649 (ClinicalTrials.gov) | May 7, 2018 | 3/7/2018 | Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss | Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV). | Alzheimer Disease;Parkinson Disease;Healthy Volunteers | Drug: [18F]MNI-1126 | Invicro | NULL | Completed | 18 Years | 55 Years | All | 12 | Phase 1 | United States |
| 39 | NCT04265027 (ClinicalTrials.gov) | February 20, 2018 | 7/2/2020 | Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC) | An Open Label, Randomised, Two Period, Crossover Study to Assess Bioavailability, Bioequivalence and S COMT Activity Between Two Active Pharmaceutical Ingredient Sources of Opicapone at Two Different Dosage Strengths (50 mg and 25 mg) After Single and Multiple Dose Administrations Under Fasting Conditions in Healthy Volunteers. | Parkinson Disease | Drug: 50 mg BIA 9 1067;Drug: 25 mg BIA9 1067;Drug: 50 mg Ongentys;Drug: 25 mg Ongentys | Bial - Portela C S.A. | NULL | Completed | 18 Years | 55 Years | All | 72 | Phase 1 | United Kingdom |
| 40 | NCT03272165 (ClinicalTrials.gov) | October 17, 2017 | 29/6/2017 | Single Ascending Dose Study of MEDI1341 in Healthy Volunteers | A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers | Parkinson's Disease | Drug: MEDI1341;Drug: Placebo | AstraZeneca | Covance;MMS Holdings, Inc;Catalent;Takeda | Completed | 18 Years | 80 Years | All | 50 | Phase 1 | United States;United Kingdom |
| 41 | NCT04162275 (ClinicalTrials.gov) | August 15, 2017 | 22/9/2019 | A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Tolerance and Pharmacokinetics Study of Oral Taking Finamine Tablets in Chinese Healthy-adult Subjects | A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Tolerance and Pharmacokinetics Study of Oral Taking Finamine Tablets in Chinese Healthy-adult Subjects | Parkinson Disease | Drug: Finamine tablets;Drug: Placebo tablets | Yiling Pharmaceutical Inc. | NULL | Completed | 18 Years | 65 Years | All | 34 | Phase 1 | China |
| 42 | NCT03116295 (ClinicalTrials.gov) | June 20, 2017 | 12/4/2017 | Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone | A Comparative, Randomized, Open-label, Fasted, Single-dose, 2-way Crossover Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone in Healthy Subjects | Parkinson Disease | Drug: Opicapone (OPC) | Bial - Portela C S.A. | NULL | Completed | 18 Years | 55 Years | All | 56 | Phase 1 | Germany |
| 43 | NCT03140956 (ClinicalTrials.gov) | April 19, 2017 | 12/4/2017 | Pharmacokinetic of Levodopa Study in Healthy Males | Pharmacokinetics of Levodopa After Repeated Doses of Different Pellet Formulations; An Open, Randomized Study With Crossover Design in Healthy Male Subjects | Parkinson Disease | Drug: Levodopa, carbidopa, ODM-104 | Orion Corporation, Orion Pharma | NULL | Completed | 18 Years | 65 Years | Male | 20 | Phase 1 | Finland |
| 44 | NCT03068481 (ClinicalTrials.gov) | February 20, 2017 | 26/2/2017 | Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease | A Phase I Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease | Parkinson Disease | Drug: KDT-3594;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | 74 Years | All | 36 | Phase 1 | Japan |
| 45 | NCT03119194 (ClinicalTrials.gov) | January 27, 2017 | 13/4/2017 | Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067 | An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067 in Healthy Male Subjects | Parkinson Disease | Drug: [14C]-BIA 9-1067 | Bial - Portela C S.A. | NULL | Completed | 30 Years | 65 Years | Male | 7 | Phase 1 | United Kingdom |
| 46 | NCT03022799 (ClinicalTrials.gov) | November 2016 | 27/12/2016 | Phase I, KM-819 in Healthy Subjects for Parkinson's Disease | A First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects | Parkinson's Disease | Drug: KM-819;Drug: Placebo | Kainos Medicine Inc. | NULL | Completed | 19 Years | 45 Years | All | 88 | Phase 1 | Korea, Republic of |
| 47 | NCT02785978 (ClinicalTrials.gov) | June 2016 | 11/5/2016 | Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers | Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers | Parkinson Disease;Healthy Volunteers | Drug: Levodopa acute challenge;Other: Controlled environment tests (series of tasks of everyday life);Other: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS;Device: ActiMyo recording;Other: Diary completion | Institut de Myologie, France | NULL | Completed | 18 Years | N/A | All | 30 | N/A | France |
| 48 | NCT02639221 (ClinicalTrials.gov) | January 2016 | 17/12/2015 | A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects | PXT002331 A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects | Parkinson's Disease | Drug: PXT002331 | Prexton Therapeutics | NULL | Completed | 18 Years | 60 Years | Both | 64 | Phase 1 | United Kingdom |
| 49 | JPRN-UMIN000019654 | 2015/11/06 | 06/11/2015 | The effect of rich-hydrogen water drinking to gut peptide | The effect of rich-hydrogen water drinking to gut peptide - The effect of rich-hydrogen water drinking to gut peptide | Parkinson's disease, healthy control | hydrogen water natural water | Nagoya graduate school of medicine university | NULL | Pending | 20years-old | 80years-old | Male and Female | 40 | Not applicable | Japan |
| 50 | NCT02562768 (ClinicalTrials.gov) | September 30, 2015 | 28/9/2015 | A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease | Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3154207 in Healthy Subjects and Subjects With Parkinson's Disease | Parkinson's Disease | Drug: LY3154207;Drug: Placebo | Eli Lilly and Company | NULL | Completed | 20 Years | N/A | All | 80 | Phase 1 | United States |
| 51 | NCT02554734 (ClinicalTrials.gov) | August 2015 | 10/6/2015 | Pharmacokinetic Study in Healthy Volunteers | Pharmacokinetics of Levodopa After Repeated Doses of Carbidopa, ODM-104 and Levodopa: an Open, Randomised Study With Crossover Design in Healthy Males and Females | Parkinson's Disease | Drug: levodopa, carbidopa, ODM-104;Drug: levodopa, carbidopa, entacapone | Orion Corporation, Orion Pharma | NULL | Completed | 18 Years | 65 Years | Both | 15 | Phase 1 | Finland |
| 52 | NCT02459886 (ClinicalTrials.gov) | July 1, 2015 | 29/5/2015 | Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease | A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects With Early Parkinson's Disease | Parkinson's Disease;Healthy | Drug: BIIB054;Drug: Placebo | Biogen | NULL | Completed | 40 Years | 80 Years | All | 66 | Phase 1 | United States |
| 53 | NCT02604914 (ClinicalTrials.gov) | May 2015 | 3/11/2015 | A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects | 1) To Identify the Concentration of CD That Provides Optimal Bioavailability of a Concomitant Fixed Concentration of LD Infused SC Continuously; 2) To Compare the Bioavailability of the Optimal LD/CD Solution to That of LD/CD Intestinal Gel | Parkinson's Disease | Drug: ND0612;Drug: LCIG | NeuroDerm Ltd. | Quotient Clinical | Completed | 30 Years | 65 Years | All | 36 | Phase 1 | United Kingdom |
| 54 | NCT02486432 (ClinicalTrials.gov) | April 2015 | 22/6/2015 | A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) | A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Doses Administered Using a Divided Dose Approach | Parkinson's Disease | Drug: Levodopa/Carbidopa (Sinemet) | NeuroDerm Ltd. | Quotient Clinical | Completed | 40 Years | 65 Years | Both | 6 | Phase 1 | NULL |
| 55 | JPRN-UMIN000016485 | 2015/02/25 | 09/02/2015 | Pilot study about imaging method of 18F-fluoro-dopa and 11C-raclopride in Parkinson's disease and Parkinson's syndrome | Pilot study about imaging method of 18F-fluoro-dopa and 11C-raclopride in Parkinson's disease and Parkinson's syndrome - PD-1 | Healthy subjects, Parkinson's disease patients and Parkinson's syndrome patients | Intravenous injection of 18F-fluoro-dopa and 11C-raclopride PET imaging | Institute of Biomedical Research and Innovation | NULL | Complete: follow-up complete | 35years-old | Not applicable | Male and Female | 20 | Not selected | Japan |
| 56 | NCT03116308 (ClinicalTrials.gov) | November 21, 2014 | 12/4/2017 | Effect of Food on Opicapone | Effect of Food on Opicapone Bioavailability and Pharmacodynamics in Healthy Subjects | Parkinson Disease | Drug: Opicapone (OPC) | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 28 | Phase 1 | NULL |
| 57 | JPRN-JapicCTI-142702 | 01/11/2014 | 12/11/2014 | A Phase 1 Study of ONO-2160/CD | A Phase 1 study on single and multiple oral dose administration of ONO-2160/CD in healthy adult male subjects and on multiple oral dose administration of ONO-2160/CD in Parkinson's disease patients | Parkinson's disease | Intervention name : ONO-2160/CD Dosage And administration of the intervention : Oral administration Control intervention name : Levodopa/carbidopa hydrate INN of the control intervention : Levodopa/carbidopa hydrate Dosage And administration of the control intervention : Oral administration | ONO PHARMACEUTICAL CO.,LTD. | NULL | BOTH | 34 | Phase 1 | NULL | |||
| 58 | NCT02312232 (ClinicalTrials.gov) | November 2014 | 2/12/2014 | Pharmacokinetic Study in Healthy Males | Pharmacokinetics of Levodopa, Carbidopa, 3-OMD and ODM-104 After Repeated Doses of Different Formulations: an Open, Randomised, Multicentre Study With Crossover Design in Healthy Males | Parkinson's Disease | Drug: levodopa, carbidopa, ODM-104 | Orion Corporation, Orion Pharma | NULL | Completed | 18 Years | 65 Years | Male | 20 | Phase 1 | Finland |
| 59 | NCT02183519 (ClinicalTrials.gov) | October 2014 | 2/7/2014 | Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease | Respiratory Kinematics of Reflex and Voluntary Cough in Healthy Older Adults and Parkinson's Disease | Cough;Parkinson's Disease | Drug: Capsaicin;Other: Voluntary cough test | University of Florida | NULL | Completed | 55 Years | 85 Years | All | 44 | Phase 1/Phase 2 | United States |
| 60 | NCT02174250 (ClinicalTrials.gov) | June 2014 | 24/6/2014 | The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers. | Effect of a Strong Enzyme Inducer, Rifampin, on the Single-Dose Pharmacokinetics of Istradefylline in Healthy Subjects | Parkinson's Disease | Drug: Istradefylline 40 mg;Drug: Rifampin 300mg BID + istradefylline 40mg Day 8 only | Kyowa Hakko Kirin Pharma, Inc. | NULL | Completed | 18 Years | 65 Years | Both | 20 | Phase 1 | United States |
| 61 | NCT02046447 (ClinicalTrials.gov) | May 2014 | 23/1/2014 | Neuroimaging of Dystonia | Neuroimaging of Dystonia: The Bachmann-Strauss Dystonia and Parkinson Disease Center of Excellence at the University of Florida | Primary Cervical Dystonia;DYT 1 Dystonia | Drug: Primary Cervical Dystonia (Trihexyphenidyl);Other: Controls Primary Cervical Dystonia (Trihexyphenidyl);Other: DYT 1 Dystonia (Healthy Control);Other: DYT 1 Dystonia | University of Florida | Bachmann Strauss Dystonia & Parkinson Foundation, Inc. | Completed | 7 Years | 70 Years | All | 20 | N/A | United States |
| 62 | NCT02305017 (ClinicalTrials.gov) | March 2014 | 28/11/2014 | Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers | Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers | Parkinson's Disease | Drug: BIA 9-1067;Drug: Paracetamol | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 28 | Phase 1 | NULL |
| 63 | NCT02111330 (ClinicalTrials.gov) | March 2014 | 20/3/2014 | Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy Volunteers | Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy Volunteers | Parkinson Disease | Drug: PBF-509;Drug: Placebo | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Palo Biofarma, S.L | Completed | 18 Years | 45 Years | Both | 16 | Phase 1 | Spain |
| 64 | NCT02305030 (ClinicalTrials.gov) | March 2014 | 28/11/2014 | Effect of Opicapone at Steady State on Warfarin Pharmacokinetics | Effect of Opicapone at Steady State on Warfarin Pharmacokinetics in Healthy Volunteers | Parkinson's Disease | Drug: BIA 9-1067;Drug: Warfarin | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | Both | 20 | Phase 1 | NULL |
| 65 | NCT02095171 (ClinicalTrials.gov) | March 2014 | 14/3/2014 | Single Ascending Dose Study of PRX002 in Healthy Subjects | A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects | Parkinson's Disease | Drug: PRX002;Other: Placebo | Prothena Biosciences Limited | Hoffmann-La Roche | Completed | 21 Years | 65 Years | Both | 40 | Phase 1 | United States |
| 66 | NCT02305316 (ClinicalTrials.gov) | February 2014 | 28/11/2014 | Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone | Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone in Healthy Volunteers | Parkinson Disease | Drug: BIA 9-1067 non-micronized;Drug: BIA 9-1067 micronized | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 28 | Phase 1 | NULL |
| 67 | NCT02103894 (ClinicalTrials.gov) | February 2014 | 12/2/2014 | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects | Alzheimer's Disease (AD);Parkinson's Disease (PD);Chronic Traumatic Encephalopathy (CTE);Progressive Supranuclear Palsy (PSP);Frontal Temporal Dementia (FTD);Pick's Disease;Tauopathies | Drug: [18F]T807 ([18F]MNI-777) | Molecular NeuroImaging | Institute for Neurodegenerative Disorders | Completed | 18 Years | 85 Years | Both | 16 | Phase 1 | United States |
| 68 | JPRN-JapicCTI-132189 | 01/6/2013 | 12/07/2013 | A Phase 1 Study of ONO-2160/CD | A Phase 1 study on single oral dose administration of ONO-2160/CD in healthy adult male subjects and Parkinson's disease patients | Parkinson's disease | Intervention name : ONO-2160/CD Dosage And administration of the intervention : Oral administration Control intervention name : Levodopa/carbidopa hydrate INN of the control intervention : Levodopa/Carbidopa Hydrate Dosage And administration of the control intervention : Oral administration | ONO PHARMACEUTICAL CO.,LTD. | NULL | BOTH | 42 | Phase 1 | NULL | |||
| 69 | NCT01879748 (ClinicalTrials.gov) | June 2013 | 13/6/2013 | A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline | A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses (0.5, 1.0, and 2.0 mg) of Rasagiline Administered to Healthy Japanese and Caucasian Subjects | Parkinson's Disease | Drug: Rasagiline;Drug: Placebo | Teva Pharmaceutical Industries | NULL | Completed | 20 Years | 50 Years | Both | 64 | Phase 1 | United States |
| 70 | NCT01691924 (ClinicalTrials.gov) | October 2012 | 13/9/2012 | Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers | Randomized, Double Blind, Placebo Controlled First In-human Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-509 in Male Healthy Volunteers | Parkinson Disease | Drug: PBF-509;Drug: Placebo | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Palo Biofarma, S.L | Completed | 18 Years | 45 Years | Male | 56 | Phase 1 | Spain |
| 71 | NCT02764892 (ClinicalTrials.gov) | August 2012 | 25/9/2015 | A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's Disease | An Open Label Study of V81444 Using Positron Emission Tomography to Assess Occupancy of Brain Adenosine A2A Receptors & Functional & Perfusion MRI to Explore Effects on Regional Brain Activity & Perfusion in Healthy Male Volunteers | Parkinson's Disease | Drug: V81444 | Vernalis (R&D) Ltd | NULL | Completed | 25 Years | 55 Years | Male | 6 | Phase 1 | NULL |
| 72 | NCT01652313 (ClinicalTrials.gov) | May 2012 | 23/7/2012 | Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women | A Single Centre, Open-label, Multiple-dose Interventional Study Investigating the Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women | Parkinson's Disease | Drug: Rasagiline | H. Lundbeck A/S | NULL | Completed | 18 Years | 45 Years | Both | 12 | Phase 1 | China |
| 73 | NCT01486628 (ClinicalTrials.gov) | April 2012 | 4/12/2011 | Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers | A Phase I, Single Dose, Single-centre, Randomized, Double-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers | Parkinson's Disease | Drug: ND0612;Drug: Placebo | NeuroDerm Ltd. | NULL | Completed | 18 Years | 40 Years | Male | 36 | Phase 1 | Israel |
| 74 | NCT01457807 (ClinicalTrials.gov) | November 2011 | 10/10/2011 | To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers | A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Different Extended Release Formulations of Tablets of AZD3241 (300 mg) After Administration of Multiple Doses in Healthy Male and Female Volunteers | Parkinson's Disease | Drug: AZD3241 ER formulation 1;Drug: Placebo;Drug: AZD3241 Alternative titration scheme with formulation 1 or 2 | AstraZeneca | NULL | Completed | 30 Years | 65 Years | Both | 24 | Phase 1 | United Kingdom |
| 75 | NCT02170376 (ClinicalTrials.gov) | September 2011 | 19/6/2014 | The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics | The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics When Administered With Immediate-release 100/25 mg Levodopa/Carbidopa in Healthy Subjects | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Entacapone;Drug: Placebo;Drug: Levodopa/carbidopa | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 80 | Phase 1 | France |
| 76 | NCT01461083 (ClinicalTrials.gov) | September 2011 | 27/9/2011 | Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a | Phase I Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a in Subjects With Parkinson Disease and Healthy Subjects | Parkinson Disease | Drug: [18F]MPPF | Institute for Neurodegenerative Disorders | NULL | Completed | 18 Years | 90 Years | Both | 19 | Phase 1 | United States |
| 77 | NCT01424475 (ClinicalTrials.gov) | August 11, 2011 | 23/6/2011 | LRRK2 Mutation and Parkinson's Disease | LRRK2 Mutation and Parkinson's Disease: A Functional Neuroimaging and Behavioural Study Characterising the Neurocognitive Phenotype | Parkinson Disease | Genetic: Healthy;Genetic: PKD Patients | GlaxoSmithKline | NULL | Terminated | 18 Years | N/A | All | 5 | Phase 1 | United Kingdom |
| 78 | NCT01461109 (ClinicalTrials.gov) | August 2011 | 27/9/2011 | Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls | Evaluation of [18F] CFPyPB PET as a Marker of Glycine Transporter-1 (GlyT1) Receptor in Subjects With Parkinson Disease, Alzheimer Disease and Healthy Subjects | Parkinson Disease;Alzheimer Disease | Drug: [18F] CFPyPB | Institute for Neurodegenerative Disorders | NULL | Completed | 18 Years | 90 Years | Both | 4 | Phase 1 | United States |
| 79 | NCT01634568 (ClinicalTrials.gov) | August 2011 | 20/6/2012 | A Clinical Trial to Find Out V81444's Side Effects and Blood Levels in Healthy Men | A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of V81444 in Healthy Male Volunteers | Parkinson's Disease | Drug: V81444 | Vernalis (R&D) Ltd | NULL | Completed | 18 Years | 45 Years | Male | 49 | Phase 1 | United Kingdom |
| 80 | NCT01520987 (ClinicalTrials.gov) | May 2011 | 26/1/2012 | Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects | Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Compare the Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects | Parkinson Disease | Drug: BIA 9-1067;Drug: Placebo | Bial - Portela C S.A. | NULL | Completed | 18 Years | 65 Years | All | 105 | Phase 1 | United States |
| 81 | NCT01462708 (ClinicalTrials.gov) | May 2011 | 8/6/2011 | Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects | Evaluation of [18F] MK-9470 and PET as a Marker of Cannabinoid-1 Receptor Activity in Subjects With Parkinson Disease Compared With Healthy Controls | Parkinson Disease | Drug: [18F]MK-9470 | Institute for Neurodegenerative Disorders | NULL | Completed | 18 Years | 90 Years | Both | 16 | Phase 1 | United States |
| 82 | NCT02169427 (ClinicalTrials.gov) | March 2011 | 24/1/2012 | An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites | An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites Following a Single Dose Oral Administration | Parkinson's Disease (PD) | Drug: OPC | Bial - Portela C S.A. | NULL | Completed | 18 Years | 55 Years | Male | 6 | Phase 1 | Netherlands |
| 83 | NCT01435915 (ClinicalTrials.gov) | June 28, 2010 | 1/9/2011 | Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects | A Single Dose and Repeat Dose Study to Investigate the Pharmacokinetics of Ropinirole After Single and Multiple Doses of a PR-formulation in Chinese Healthy Male and Female Subjects | Parkinson Disease | Drug: Ropinirole | GlaxoSmithKline | NULL | Completed | 18 Years | 45 Years | All | 24 | Phase 1 | China |
| 84 | NCT01532115 (ClinicalTrials.gov) | May 2010 | 23/1/2012 | Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women | A Randomized, Double-blind, Placebo-controlled and Open-label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women | Parkinson Disease | Drug: BIA 9-1067;Drug: Placebo;Drug: moxifloxacin | Bial - Portela C S.A. | NULL | Completed | 18 Years | 55 Years | Both | 64 | Phase 1 | France |
| 85 | NCT01503944 (ClinicalTrials.gov) | March 2010 | 14/7/2010 | A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET) | Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers | Dementia With Lewy Bodies;Alzheimer's Disease;Parkinson's Disease | Drug: 18F-AV-133;Drug: 18F-AV-45 | Avid Radiopharmaceuticals | NULL | Completed | 50 Years | N/A | Both | 30 | Phase 1/Phase 2 | United States |
| 86 | NCT02169414 (ClinicalTrials.gov) | February 2010 | 24/1/2012 | Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics | Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics of a Single-dose of Immediate Release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects | Parkinson's Disease (PD) | Drug: BIA 9-1067 5 mg;Drug: BIA 9-1067 25 mg;Drug: levodopa/carbidopa 100/25;Drug: Placebo;Drug: levodopa/benserazide 100/25 mg | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 74 | Phase 1 | France |
| 87 | NCT01070628 (ClinicalTrials.gov) | December 2009 | 23/11/2009 | Levodopa Concentration Profile With Stalevo 75/125 mg | Levodopa Concentration Profile After Repeated Doses of Different Stalevo® Strengths With 3.5 Hours Dosing Frequency; an Open, Randomised, Crossover, Levodopa/Carbidopa Controlled Single Centre Study in Healthy Subjects, Two Parallel Groups | Parkinson's Disease | Drug: Stalevo (levodopa/ carbidopa/ entacapone);Drug: Sinemet (levodopa/carbidopa) | Orion Corporation, Orion Pharma | NULL | Completed | 18 Years | 70 Years | Both | 20 | Phase 1 | Finland |
| 88 | EUCTR2009-011093-15-DE (EUCTR) | 16/11/2009 | 23/09/2009 | The role of the neurotransmitters dopamine and acetylcholine in the interaction of selective attention and working memory. - Dopamine and Acetylcholine for Attention and Memory | The role of the neurotransmitters dopamine and acetylcholine in the interaction of selective attention and working memory. - Dopamine and Acetylcholine for Attention and Memory | Healthy volunteers MedDRA version: 12.0;Level: LLT;Classification code 10012271;Term: Dementia Alzheimer's type MedDRA version: 12.0;Classification code 10013113;Term: Disease Parkinson's | Trade Name: Nacom INN or Proposed INN: LEVODOPA Other descriptive name: L-Dopa Trade Name: Reminyl INN or Proposed INN: GALANTAMINE Other descriptive name: Galantamine hydrobromide | Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | Germany | ||
| 89 | NCT01519284 (ClinicalTrials.gov) | November 2009 | 23/1/2012 | Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic | A Double-blind, Randomised, Placebo- and Active-controlled Multiple-dose Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetics Following a Levodopa/Carbidopa 100/25 mg Single-dose in Healthy Subjects | Parkinson Disease | Drug: BIA 9-1067 5 mg;Drug: Entacapone;Drug: Placebo;Drug: levodopa/carbidopa;Drug: BIA 9-1067 15 mg;Drug: BIA 9-1067 30 mg | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 82 | Phase 1 | Portugal |
| 90 | NCT01532141 (ClinicalTrials.gov) | November 2009 | 23/1/2012 | Effect of Rasagiline on BIA 9-1067 Pharmacokinetics | Effect of Rasagiline on BIA 9-1067 Pharmacokinetics in Healthy Subjects | Parkinson Disease | Drug: BIA 9-1067;Drug: Rasagiline | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 25 | Phase 1 | France |
| 91 | NCT01532128 (ClinicalTrials.gov) | November 2009 | 23/1/2012 | Effect of BIA 9-1067 on Rasagiline Pharmacokinetics | Effect of BIA 9-1067 on Rasagiline Pharmacokinetics in Healthy Subjects | Parkinson Disease | Drug: rasagiline;Drug: BIA 9-1067 | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 24 | Phase 1 | France |
| 92 | NCT01371682 (ClinicalTrials.gov) | September 18, 2009 | 10/6/2010 | A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda | An Open Label Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets (Ropinirole XL, Marketed as REQUIP-MODUTAB™, REQUIP XL™ at 2 mg) Manufactured at Crawley and Aranda | Parkinson Disease | Drug: Ropinirole XL | GlaxoSmithKline | NULL | Completed | 18 Years | 50 Years | All | 50 | Phase 1 | Belgium |
| 93 | NCT00970229 (ClinicalTrials.gov) | July 2009 | 31/8/2009 | Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. | Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy Controls | Parkinson Disease;Huntington Disease | Drug: [123I]MNI-420 | Institute for Neurodegenerative Disorders | NULL | Completed | 18 Years | N/A | All | 19 | Phase 1 | United States |
| 94 | NCT01536366 (ClinicalTrials.gov) | June 2009 | 23/1/2012 | Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide | Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide in Healthy Volunteers | Parkinson Disease | Drug: BIA 9-1067;Drug: Repaglinide | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 27 | Phase 1 | Portugal |
| 95 | NCT02169440 (ClinicalTrials.gov) | June 2009 | 24/1/2012 | Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin | Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Warfarin | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 20 | Phase 1 | Portugal |
| 96 | NCT01515891 (ClinicalTrials.gov) | May 2009 | 19/1/2012 | Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites | An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites Following a Single-dose Oral Administration | Parkinson Disease | Drug: BIA 9-1067 | Bial - Portela C S.A. | NULL | Completed | 40 Years | 55 Years | Male | 4 | Phase 1 | Switzerland |
| 97 | NCT00875316 (ClinicalTrials.gov) | April 2009 | 2/4/2009 | Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease Patients | A Randomised, Double-blind, Multiple Dose-ascending, Placebo-controlled Study in Healthy Volunteers and Parkinson's Disease Patients to Assess the Safety, Tolerability and PK of Daily Oral Administration of Cogane™ Over One Month | Parkinson's Disease | Drug: Cogane™ (PYM50028) | Phytopharm | NULL | Completed | 40 Years | 80 Years | Both | 36 | Phase 1 | United Kingdom |
| 98 | NCT01533116 (ClinicalTrials.gov) | March 2009 | 24/1/2012 | Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide | Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects | Parkinson Disease | Drug: BIA 9-1067;Drug: Placebo;Drug: levodopa/carbidopa;Drug: levodopa/benserazide | Bial - Portela C S.A. | NULL | Completed | 25 Years | 45 Years | All | 52 | Phase 1 | Canada |
| 99 | NCT01533077 (ClinicalTrials.gov) | March 2009 | 24/1/2012 | Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa | Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa in Healthy Subjects | Parkinson Disease | Drug: BIA 9-1067;Drug: Sinemet® 100/25 mg | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 18 | Phase 1 | Canada |
| 100 | NCT02169466 (ClinicalTrials.gov) | January 2009 | 20/1/2012 | Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide | Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Placebo;Drug: Madopar® HBS | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | Male | 22 | Phase 1 | Portugal |
| 101 | NCT02169453 (ClinicalTrials.gov) | October 2008 | 20/1/2012 | Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa | Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Placebo;Drug: Sinemet® CR 100/25 | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | Male | 12 | Phase 1 | Canada |
| 102 | NCT02092168 (ClinicalTrials.gov) | October 2008 | 20/1/2012 | Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects | Single-dose and Steady-state Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects Compared With Those in Healthy Male Young Subjects | Parkinson Disease | Drug: BIA 9-1067 | Bial - Portela C S.A. | NULL | Completed | 18 Years | N/A | Male | 24 | Phase 1 | France |
| 103 | NCT02169895 (ClinicalTrials.gov) | September 2008 | 20/1/2012 | Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide | Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Benserazide: a Doubleblind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Placebo;Drug: Prolopa® | Bial - Portela C S.A. | NULL | Completed | 25 Years | 45 Years | Male | 16 | Phase 1 | Canada |
| 104 | NCT02169479 (ClinicalTrials.gov) | September 2008 | 20/1/2012 | Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa | Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa: a Doubleblind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Placebo;Drug: Sinemet® 100/25 | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | Male | 16 | Phase 1 | Canada |
| 105 | NCT02071810 (ClinicalTrials.gov) | April 2008 | 19/1/2012 | Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067 | A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Four Multiple Rising Dose Regimens of BIA 9-1067 in Healthy Male Volunteers | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Placebo | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | Male | 34 | Phase 1 | France |
| 106 | NCT00612872 (ClinicalTrials.gov) | January 2008 | 16/1/2008 | Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects | Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With Parkinson Disease or Alzheimer Disease and in Healthy Subjects | Parkinson Disease;Alzheimer Disease;Healthy Controls;Multiple Sclerosis | Drug: [123I]CLINDE | Institute for Neurodegenerative Disorders | NULL | Terminated | 30 Years | 50 Years | All | 46 | Phase 1 | United States |
| 107 | NCT01520727 (ClinicalTrials.gov) | October 2007 | 18/1/2012 | A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects | A Single Oral Ascending Dose Study to Investigate the Safety, Pharmacokinetics and Catechol-O-methyltransferase (COMT) Inhibition Profiles of BIA 9-1067 in Healthy Male Subjects | Parkinson Disease | Drug: BIA 9-1067;Drug: Placebo | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | Male | 64 | Phase 1 | France |
| 108 | NCT00460954 (ClinicalTrials.gov) | June 2007 | 16/4/2007 | A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects | An Open Label, Multiple-Dose Study ot Determine the Plasma Levodopa Profiles of Sinemet® CR (Carbidopa/Levodopa) at 4 Daily Dose Levels in Healthy Subjects | Parkinson's Disease | Drug: Sinemet® controlled release (Carbidopa/levodopa) | Bristol-Myers Squibb | NULL | Completed | 50 Years | 75 Years | Both | 20 | N/A | Canada |
| 109 | NCT00480701 (ClinicalTrials.gov) | February 2007 | 30/5/2007 | Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease | Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT as a Marker of Acetylcholine Transporter Density in the Brain of Healthy Subjects and Patients With Alzheimer Disease | Alzheimer Disease;Parkinson Disease | Drug: [123I]-IBVM | Institute for Neurodegenerative Disorders | NULL | Completed | 50 Years | N/A | Both | 26 | Phase 2 | United States |
| 110 | NCT00427674 (ClinicalTrials.gov) | January 2007 | 25/1/2007 | Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients | Phase I Evaluation of (123-I)MZINT as a Brain SPECT Tracer of Serotonin Transporters in Healthy Human Subjects | Parkinson Disease | Drug: [123I] mZINT injection and serial dynamic SPECT imaging | Institute for Neurodegenerative Disorders | Molecular NeuroImaging | Terminated | 18 Years | 70 Years | Both | 28 | Phase 1 | United States |
| 111 | EUCTR2006-005140-89-NL (EUCTR) | 11/12/2006 | 01/12/2006 | A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge study | A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge study | This postmarketing Phase I study is performed in healthy volunteers. The IMP rasagiline 1mg is indicated for the treatment of Parkinson's Disease (PD). MedDRA version: 9.1;Level: PT;Classification code 10061536 | Trade Name: Selegiline HCl 5 PCH Trade Name: Nardil Product Name: Rasagiline 1mg tablet Product Code: TVP-1012 INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesilate Product Name: Rasagiline 2 mg tablet Product Code: TVP-1012 INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesilate | TEVA Pharmaceuticals Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 160 | Phase 4 | Netherlands | ||
| 112 | NCT01964573 (ClinicalTrials.gov) | December 2006 | 14/10/2013 | Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects | A Single-site, Randomized, Double-blind, Placebo-controlled, Repeated-dose Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in 2 Different Dosages (2 mg / 24 Hours [10 cm2], 4 mg / 24 Hours [20 cm2]) in Healthy Korean Subjects | Parkinson's Disease | Drug: Rotigotine;Other: Placebo | UCB Pharma | NULL | Completed | 19 Years | 45 Years | Both | 48 | Phase 1 | Korea, Republic of |
| 113 | NCT03097211 (ClinicalTrials.gov) | July 17, 2006 | 27/3/2017 | Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg | A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg | Parkinson Disease | Drug: Placebo;Drug: BIA 6-512;Drug: Madopar® 250;Drug: Nebicapone | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 38 | Phase 1 | Portugal |
| 114 | NCT03094156 (ClinicalTrials.gov) | April 26, 2006 | 23/3/2017 | Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics | A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Entacapone 200 mg | Parkinson Disease | Drug: Placebo;Drug: BIA 6-512;Drug: Madopar® 250;Drug: Comtan® | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 39 | Phase 1 | Portugal |
| 115 | NCT03095105 (ClinicalTrials.gov) | January 24, 2006 | 23/3/2017 | Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects | An Open-label, Parallel-group Study to Compare the Pharmacokinetic Profile in Healthy Elderly Subjects Versus Healthy Young Subjects After Single and Repeated Oral Administration of BIA 6-512 (Trans-resveratrol) | Parkinson Disease | Drug: 200 mg BIA 6-512 | Bial - Portela C S.A. | NULL | Completed | 18 Years | N/A | All | 25 | Phase 1 | Germany |
| 116 | NCT02772614 (ClinicalTrials.gov) | January 2006 | 12/5/2016 | Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites | An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites Following a Single-dose Oral Administration | Parkinson's Disease | Drug: BIA 3-202 (200 mg) | Bial - Portela C S.A. | NULL | Completed | 40 Years | 55 Years | Male | 4 | Phase 1 | Switzerland |
| 117 | NCT02774564 (ClinicalTrials.gov) | September 2005 | 13/5/2016 | Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa | Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single Dose of Controlled-release 200/50 mg Levodopa/Carbidopa (Sinemet® cr 200/50): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy Volunteers | Parkinson's Disease | Drug: BIA 3-202;Drug: Placebo;Drug: Sinemet® | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | Both | 16 | Phase 1 | Portugal |
| 118 | NCT02778594 (ClinicalTrials.gov) | September 2005 | 18/5/2016 | Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide | Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide (Madopar® HBS 125): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy Volunteers | Parkinson's Disease (PD) | Drug: BIA 3-202;Drug: Placebo;Drug: levodopa 100 mg / benserazide 25 mg | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | Both | 17 | Phase 1 | Portugal |
| 119 | NCT03095092 (ClinicalTrials.gov) | May 23, 2005 | 23/3/2017 | Effect of Food on BIA 6-512 (Trans-resveratrol) | The Effect of Food on the Pharmacokinetics of a Single 400 mg Oral Dose of BIA 6-512 (Trans-resveratrol) in Healthy Subjects | Parkinson Disease | Drug: BIA 6-512 400 mg | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 24 | Phase 1 | Portugal |
| 120 | NCT03093389 (ClinicalTrials.gov) | May 11, 2005 | 22/3/2017 | Tolerability and Steady-state Pharmacokinetics of BIA 6-512 | A Double-blind, Randomised, Placebo-controlled, Rising Multiple-dose Study to Investigate the Tolerability and Steady-state Pharmacokinetics of BIA 6-512 (Trans-resveratrol) in Healthy Volunteers | Parkinson Disease | Drug: BIA 6-512;Drug: Placebo | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 40 | Phase 1 | Portugal |
| 121 | NCT03091868 (ClinicalTrials.gov) | November 3, 2004 | 21/3/2017 | Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics | A Double-blind, Randomised, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability and Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Carbidopa 100/25 mg or With a Single-dose of Levodopa/Carbidopa 100/25 mg Plus a Single-dose of Entacapone 200 mg | Parkinson Disease | Drug: Placebo oral capsule;Drug: Sinemet® 100/25;Drug: Comtan®;Drug: BIA 6-512 25 mg;Drug: BIA 6-512 100 mg | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 80 | Phase 1 | Portugal |
| 122 | NCT03091543 (ClinicalTrials.gov) | May 4, 2004 | 21/3/2017 | Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics | A Double-blind, Randomised, Crossover, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 100/25 mg | Parkinson Disease | Drug: Madopar® HBS 125;Drug: Placebo;Drug: BIA 6-512 25 mg dose;Drug: BIA 6-512 50 mg dose;Drug: BIA 6-512 100 mg dose;Drug: BIA 6-512 200 mg dose | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 20 | Phase 1 | Portugal |
| 123 | NCT00032812 (ClinicalTrials.gov) | March 2002 | 3/4/2002 | The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's Disease | Motor Memory: Study of the Role of Dopamine in Healthy Subjects and Patients With Parkinson's Disease Using PET and EEG | Parkinson Disease;Healthy | Drug: Raclopride | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 64 | N/A | United States |
| 124 | NCT02772627 (ClinicalTrials.gov) | September 2001 | 12/5/2016 | Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202 | A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202 in Healthy Volunteers. | Parkinson's Disease | Drug: Nebicapone;Drug: Placebo | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | Both | 22 | Phase 1 | Portugal |
| 125 | NCT02763839 (ClinicalTrials.gov) | April 2001 | 4/5/2016 | Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg) | Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg): a Double-blind, Randomised, Crossover, Placebo Controlled Study in Healthy Volunteers | Parkinson's Disease | Drug: BIA 3-202;Drug: Placebo;Drug: Sinemet 25/100 | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | Both | 19 | Phase 1 | Portugal |
| 126 | NCT02763852 (ClinicalTrials.gov) | April 2001 | 4/5/2016 | Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg) | Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg): a Double-blind, Randomised, Crossover, Placebo Controlled Study in Healthy Volunteers | Parkinson's Disease | Drug: BIA 3-202;Drug: Placebo;Drug: Madopar® 125 | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | Both | 18 | Phase 1 | Portugal |
| 127 | NCT02763800 (ClinicalTrials.gov) | September 2000 | 4/5/2016 | Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202 | Double-Blind, Randomised, Placebo-Controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202, in Young Healthy Volunteers | Parkinson's Disease | Drug: BIA 3-202;Drug: Placebo | Bial - Portela C S.A. | NULL | Completed | 18 Years | 35 Years | Male | 33 | Phase 1 | United Kingdom |
| 128 | NCT02763787 (ClinicalTrials.gov) | April 2000 | 4/5/2016 | Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202 | A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Single Doses of BIA 3-202 in Healthy Volunteers. | Parkinson's Disease | Drug: BIA 3-202;Drug: Placebo | Bial - Portela C S.A. | NULL | Completed | 18 Years | 35 Years | Male | 71 | Phase 1 | United Kingdom |
| 129 | NCT00004451 (ClinicalTrials.gov) | March 1998 | 18/10/1999 | Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients | Parkinson Disease | Drug: Glucose | National Institute of Mental Health (NIMH) | University of Virginia | Completed | 18 Years | N/A | Both | 120 | N/A | United States | |
| 130 | NCT00001258 (ClinicalTrials.gov) | November 26, 1993 | 3/11/1999 | Studies of Frontal Lobe Brain Functioning in Schizophrenia | Studies of Frontal Lobe Function During Cognitive Stimulation as Measured With Oxygen-15 Water Positron Emission Tomography in Normal Subjects and Patients With Neuropsychiatric Disorders | Healthy Subjects;Schizophrenia;Parkinson Disease | Drug: Oxygen-15 Water | National Institute of Mental Health (NIMH) | NULL | Completed | 18 Years | 90 Years | All | 1039 | United States |